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Abstract
Background: Press releases are a popular vehicle to disseminate health information to the lay media. While the quality of
press releases issued by scientific conferences and medical journals has been questioned, no efforts to assess
pharmaceutical industry press releases have been made. Therefore, we sought to systematically examine pharmaceutical
company press releases about original research for measures of quality.
Methodolgy/Principal Findings: Press releases issued by the ten top selling, international pharmaceutical companies in the
year 2005 were selected for evaluation. A total of 1028 electronic press releases were issued and 235 were based on original
research. More than half (59%) reported results presented at a scientific meeting. Twenty-one percent of releases were not
explicit about the source of original data. While harms or adverse events were commonly cited (76%), study limitations were
rarely noted (6%). Almost one-third (29%) of releases did not quantify study results. Studies presented in abstract form were
subsequently published within at least 20 months in 53% of cases.
Conclusions: Pharmaceutical company press releases frequently report basic study details. However, readers should be
cautioned by the preliminary nature of the data and lack of identified limitations. Methods to improve the reporting and
interpretation of drug company press releases are desirable to prevent misleading media coverage.
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Introduction
The press release was first introduced in 1906 by Ivy Lee,
considered the father of modern public relations [1]. Since then,
the medical world increasingly relies on the press release to attract
media attention and disseminate health information thought to
have ‘‘news’’ value to the general public. Press releases are issued
routinely by the pharmaceutical industry. These enterprises use
this medium to maintain media visibility and for direct
communication with shareholders, the medical community, and
newsmakers at large.
There is growing interest in news releases from scientific
conferences and medical journals. Studies with accompanying
press releases are better represented in the lay media and
considered more newsworthy by health journalists [2,3]. Yet,
many caution that press releases do not serve as a precise medical
reference. They frequently report incomplete information or omit
basic study data [4]. In addition, an editorial process to confirm
accuracy of the results is usually lacking.
Since the motivation for issuing press releases by profit-driven
companies may be different than those from medical journals or
scientific conferences, it is important to examine the quality of this
information for commercial bias. No attempts to analyze drug
company press releases have been made despite descriptions about
the poor quality of conference and journal press releases. Thus,
our objective was to systematically examine pharmaceutical
company press releases of original research for descriptors of
study quality. We did not seek to confirm accuracy of the factual
content contained within the releases.
Methods
We identified international pharmaceutical companies based on
their 2004 worldwide prescription sales [5]. We selected the top 10
companies, which represent ,90% of the global pharmaceutical
market share [6]. Only those with publicly accessible web sites and
available electronic press releases for the year 2005 (fifth-placed
Merck & Co. was excluded as study press releases were not
publicly available) were selected for study (Appendix S1). We only
included English language releases, which referred to original
research. Releases about financial updates or organizational policy
were excluded.
No standard format to evaluate press releases exists. However, a
previous study developed a coding scheme to record quality
measures relevant to journal press releases (4 and Woloshin,
personal communication, 2005). We modified this tool with what
we believe to be important descriptors of press release quality
based on other methodological tools used for critical appraisal [7].
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design, study subjects, duration of follow-up and mention of harm
or limitations of the research (Appendix S2). We also documented
if results were quantified as relative or absolute risks. We
performed PubMed and MEDLINE searches until August 2007
(minimum 20 months) to identify subsequent publication of
abstracts presented at scientific meetings and categorized them
based on their Institute for Scientific Information 2007 impact
factor [8]. Journals were classified as ‘‘high-impact’’ if their impact
factor was among the top 10 in their relevant category.
All releases were coded by a study author (BK). A random
sample of 10% of press releases for each company was coded by
another author (ES) to establish the reliability of the coding
scheme. Inter-rater reliability using the k statistic ranged from 0.80
to 1.0 with a mean of 0.90, representing ‘‘almost perfect’’
agreement [9].
Results
Between January 1, 2005 and December 31, 2005, the 10
companies issued a total of 1028 electronic press releases. Almost a
quarter of these (n=235, 23%) were based on original research
but the number varied among companies (range 7–54). The most
commonly represented medical disciplines included studies of
cardiovascular (20%), oncology (20%) or HIV/AIDS (9%)
research.
More than half (59%) of the press releases reported results
presented as abstracts at a scientific meeting (Table 1). Some (20%)
described studies published in peer-reviewed journals but many
(38%) did not provide full reference to the corresponding journal
article. The remainder of releases (21%) did not mention the
source of original data at all.
Basic study details were frequently reported. Of those reporting
study design, 67% were randomized controlled trials (RCTs), 14%
were uncontrolled trials and the remainder (9%) included survey
and cohort studies. Study size was frequently recorded. The
majority (60%) were medium-sized studies (31–1000 people)
involving human subjects (99%). Follow-up time and quantifica-
tion of study results was included in 71% and more common in
press releases of RCTs. When quantified, 27% provided a base
rate while 73% presented a ratio measure, most commonly as a
relative risk.
Harms or adverse events were cited in about three-quarters
(76%) of releases but study limitations (6%) were rarely noted, with
the majority (62%) reporting the results as preliminary. Almost
one-half of releases (47%) quoted a study author who was usually
the principal investigator. The authors’ comments typically
emphasized the benefit of the intervention but only 10% described
limitations of the research. Additional sources of study funding
were also reported (42%) and typically involved partnership with
another pharmaceutical company.
Of the 138 scientific meeting-related press releases, 55 (41%)
abstracts, primarily of RCTs, were subsequently published in high-
impact journals, 17 (12%) in low-impact journals and 64 (47%)
remained unpublished when evaluated at a minimum of 20
months after the scientific conferences (Figure 1).
Discussion
To our knowledge, this is the first study to systematically
appraise pharmaceutical press releases. Our large sample provides
useful information about the quality of press release reporting of
original research.
Our study shows that industry press releases are generally good
at providing basic study details, but may provide incomplete
information needed for a reader to gauge a study’s clinical
implications. Many press releases focused on research presented at
scientific conferences, often considered the forefront of current
knowledge. However, this information is frequently based on
preliminary data without peer-review and may omit limitations
such as small study size, uncontrolled study design or short
duration of follow up [10,11]. In turn, this can mislead readers
about the validity of results [12]. Furthermore, several releases
were not explicit about the source of original data and only a
fraction noted any study limitations. A third of releases did not
quantify study results, and of those that did, results were presented







Press releases based on original research 158 (67) 77 (33) 235 (100)
Median sentences 46 35
Study presented at scientific meeting 92 (67) 46 (33) 138 (59)
Study published in medical journal 31 (66) 16 (34) 47 (20)
Quality Measures
No. (%)
Study size reported 137 (72) 54 (28) 191 (81)
Study subjects reported 162 (69) 73 (31) 235 (100)
Follow-up time reported 119 (72) 47 (28) 166 (71)
Study results quantified 118 (72) 46 (28) 164 (71)
Harms/adverse events reported 128 (72) 50 (28) 178 (76)
Limitation noted 10 (77) 3 (23) 13 (6)
Study author quoted 77 (70) 33 (30) 110 (47)
Other funding source cited 69 (70) 30 (30) 99 (42)
RCT, randomized controlled trial; non-RCT includes press releases of
uncontrolled studies, controlled but not randomized studies, surveys,
diagnostic test studies and unknown study type.
doi:10.1371/journal.pone.0002828.t001
Figure 1. Percentage of scientific meeting abstracts published
within 20 months. ‘‘High-impact journal’’ was classified as a journal
within the top 10-impact factor rating in the relevant specialty area (e.g.
cardiovascular, oncology), general medicine category or research and
experimental medicine category. Low-impact journals were not in any
of the 3 top lists.
doi:10.1371/journal.pone.0002828.g001
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perceived magnitude of effect [13].
It is not surprising that randomized controlled trials were
overrepresented in press releases as these studies have considerable
influence on clinical practice. In addition, widespread illnesses
such as heart disease, cancer and HIV/AIDS were the most cited
medical disciplines. Previous work has shown that medications
used to treat chronic disorders are the focus of considerable
advertising efforts by pharmaceutical companies and may garner
more media attention [14,15].
We found no other work evaluating press releases from
pharmaceutical companies. However, Woloshin et al. examined
the quality of press releases issued by medical journals [4]. Similar
to our data, they found that releases do not routinely highlight
limitations and often use formats that exaggerate study findings.
Our study has several limitations. First, we only examined
archived releases for the year 2005 available in electronic format
on corporate websites. This led to the exclusion of fifth-ranked
Merck & Co. While results may not be generalizable to smaller
drug companies, we selected the world’s most successful
pharmaceutical manufacturers who all have strong media presence
and public relations practices. Second, we did not corroborate
press release content with subsequent publication, as our aim was
to report study characteristics rather than test data accuracy. This
approach may be justified as previous work has shown that
abstracts often differ from published peer-reviewed results. In a
study examining transition of scientific meeting abstracts to full-
length journal article, 41% of publications exhibited significant
discrepancies when compared to the original abstract data [16].
Third, the findings are predicated on our construct of what
constitutes a good quality press release. Our instrument was based
on previous work and established guides but results may differ with
other assessments tools. Lastly, while we know that journalists
frequently rely on press releases as a source of health topic ideas,
the association between releases and ensuing coverage in
newspaper, radio or television stories was not investigated [17].
Our findings suggest that the quality of pharmaceutical press
releases needs improvement. Simple ways of enhancing quality
would include referencing original data to confirm press release
content, quantifying study results in clinically meaningful ways,
and identifying important limitations so that the generalizability of
results across different populations and settings can be appreciated.
It is unlikely that the pharmaceutical industry will change its
reporting of original research. Thus, journalists and newsmakers
should be aware of the shortcomings of press release data and
learn to scrutinize this information before adoption into health
news for public consumption. Creating a standardized ‘‘checklist’’
of quality indicators is one possible appraisal tool for readers to
use.
Future studies should explore the process by which press release
content is selected, edited and later distributed. As with all health
information, critical review is essential to contextualize its content.
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